Aethlon Medical announced today that the United States Food and - TopicsExpress



          

Aethlon Medical announced today that the United States Food and Drug Administration (FDA) has approved a clinical protocol to treat Ebola-infected individuals in the U.S. with the Aethlon Hemopurifier®. The Ebola treatment protocol resulted from the submission of a supplement to an Investigation Device Exemption (IDE) previously approved by FDA. The protocol allows for an investigational study to be conducted at up to 10 U.S. clinical sites, and up to 20 U.S. subjects may be enrolled to receive the treatment protocol. As the approved Ebola treatment protocol is a deviation from the HCV protocol, Aethlon is required to clearly distinguish data collected in the supplemental Ebola protocol study from data derived from the Companys HCV trials. The Company may not combine data from the two studies. Read the full press release for additional details: bit.ly/1AmtDhP
Posted on: Fri, 02 Jan 2015 16:16:53 +0000

Trending Topics



Recently Viewed Topics




© 2015